Metabolic Peptides
GLP-2 TZ
Research Grade≥99% PurityLyophilized
A dual GIP and GLP-1 receptor agonist studied for incretin receptor binding assays.
Dosage
$85.00
Quantity
Bundle & Save
We accept
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Frequently Bought Together
Bacteriostatic Water
10 ml
$10.00
GLP-3 RT
10 mg
$110.00
NAD+
500 mg
$70.00
GHK-Cu
50 mg
$65.00
BPC-157
5 mg
$45.00
Melanotan II
10 mg
$55.00
Tesamorelin
10 mg
$85.00
TB-500
10 mg
$45.00
MOTS-c
10 mg
$75.00
Research Summary
GLP-2 TZ
Published research data and clinical observations
🔬
Research Phase
Extensive clinical data available
💉
Administration
5, 10, or 15 mg once weekly
🧬
Key Mechanism
First-in-class twincretin
📄
Publications
SURPASS + SURMOUNT trials
👥
Subjects Studied
Phase III clinical programs
What Makes GLP-2 TZ Different?
The Science, Simplified
Two Receptors, One Molecule
GLP-2 TZ is the first dual-receptor agonist — it activates both GIP and GLP-1 pathways simultaneously. These two incretin hormones normally work together after meals, but this peptide amplifies both signals far beyond what food alone triggers.
GIP
Strongest
GIP Receptor
Glucose-dependent Insulinotropic Polypeptide
Enhances insulin secretion
Improves fat metabolism
Synergizes with GLP-1
GLP-1
Strong
GLP-1 Receptor
Glucagon-like Peptide-1
Reduces appetite centrally
Slows gastric emptying
Improves blood sugar
WHY DUAL BEATS SINGLE
The Twincretin Advantage
Single GLP-1 agonists like semaglutide hit one receptor. GLP-2 TZ hits two — and the results show it in head-to-head trials:
Beat semaglutide in SURPASS-2: 22.5% weight loss vs 15.3% — the largest difference ever seen between two anti-obesity drugs.
GLP-1 onlySemaglutide: -15.3%
GLP-2 TZ (dual)GIP + GLP-1: -22.5%
What Researchers Observed
22.5%
Mean body weight reduction (15mg)
SURMOUNT-1 trial, 72 weeks, n=2,539
64%
86%
90%
92%
Key Milestones Achieved
96%
96.3% of 15mg group (SURMOUNT-1)
63%
63% of 15mg group at 72 weeks
86%
81-86% across doses (SURPASS-1)
For context:SURMOUNT-1 (Jastreboff et al., NEJM, 2022) randomized 2,539 adults with obesity to tirzepatide 5/10/15mg or placebo for 72 weeks. Weight reduction was 16.0%, 21.4%, and 22.5% respectively vs 3.1% placebo. SURPASS-1 (Rosenstock et al., Lancet, 2021) showed HbA1c reductions of 1.87-2.07% in T2D. GLP-2 TZ is for research use only.
Compound Information
Technical specifications
❄️ Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
📋 Development Status
Where It Stands
Extensively StudiedResearch Use Only
DeveloperEli Lilly
Trial ProgramSURPASS / SURMOUNT
ResultsMultiple Phase III trials completed
This page summarizes published research for informational purposes only. These products are sold exclusively as research chemicals and are not intended for human consumption. Always consult peer-reviewed literature for complete study details.
Your Cart
Your cart is empty